CVRx, Inc. — 2022 Form 10-K Summary
Business context and reporting period
CVRx is a commercial-stage medical-device company whose revenue is primarily from Barostim, an implantable neuromodulation device indicated in the U.S. to improve symptoms in certain patients with heart failure with reduced ejection fraction (HFrEF). This filing covers the fiscal year ended December 31, 2022; it does not provide standalone fourth-quarter results.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $22.5 million | $13.0 million |
| Gross profit / margin | $17.5 million / 78% | $9.4 million / 72% |
| Operating expenses | $60.0 million | $35.4 million |
| Loss from operations | $42.5 million | $26.0 million |
| Net loss | $41.4 million | $43.1 million |
| Net loss per share, basic and diluted | $2.02 | $4.16 |
| Cash used in operating activities | $42.7 million | $27.7 million |
- U.S. revenue rose 97% to $18.0 million; Europe revenue rose 14% to $4.4 million. U.S. HFrEF revenue was $17.6 million, with 587 U.S. HFrEF revenue units versus 290 in 2021. Active U.S. implanting centers increased to 106 from 46.
- At year-end, cash and cash equivalents were $106.2 million, down from $142.1 million. Current assets were $122.9 million and current liabilities $8.1 million.
- Long-term debt was $6.7 million net of debt costs, following a $7.5 million draw under the Innovatus facility. The facility permits up to $50 million in total borrowings, subject to milestones and revenue conditions; it is secured by substantially all personal property and matures January 2028.
- Accumulated deficit was $436.2 million. Research and development expense was $10.0 million, up from $7.5 million; selling, general and administrative expense was $50.0 million, up from $27.9 million.
Material changes versus 2021
- Revenue grew 72%, reflecting U.S. commercial expansion, more sales territories and implanting centers, and increased physician and patient awareness. Management said procedure volumes returned to more normal levels from March 2022 after COVID-19-related disruptions.
- Gross margin increased six percentage points, primarily from lower unit costs and higher average selling prices, partly offset by a greater share of full-system sales.
- Operating expenses increased 70%, led by higher compensation and headcount, as well as commercial, travel, marketing and public-company costs. Despite higher revenue and gross profit, operating loss widened.
- Net loss narrowed slightly, mainly because 2021 included a large non-cash fair-value expense for convertible preferred stock warrants and a debt-extinguishment loss. Interest expense also fell after repayment of the prior Horizon debt.
- Operating cash use increased by $15.0 million year over year; financing cash inflow was much lower than in 2021, when the IPO generated $133.2 million net proceeds.
Outlook, risks and notable items
- Management expected continued losses for at least several years, while stating that cash resources, the term-loan facility and revenue were expected to fund forecast operating liquidity, capital expenditures and debt service for at least three years. The company cautioned that estimates rely on assumptions and additional funding could be needed.
- No numerical revenue or profitability guidance is provided. Priorities include expanding the U.S. sales organization, building awareness and reimbursement access, and investing in product improvements and clinical evidence.
- At the filing date, CVRx had reached the required 320th event in the BeAT-HF post-market study and expected to unblind and announce data in the first quarter of 2023. Outcomes could affect adoption and a possible request for a broader FDA heart-failure treatment claim.
- The European AIMDD CE certificate expired in December 2022. Transition rules allowed eligible product already placed on the market to be sold through 2025, and CVRx had placed about one year of European product in the market to support sales through 2023. Continued sales thereafter depended on MDR approval or an extension; timing and regulatory outcome were uncertain.
- The CMS outpatient transitional pass-through payment was scheduled to expire at the end of 2023. Management identified reimbursement adequacy and continued coverage as important to adoption.
- Additional risks include dependence on one principal product, persistent losses and cash burn, competition, limited-source suppliers, reliance on one manufacturing site, regulatory and clinical uncertainty, and potential constraints under debt covenants. The company reported no material legal proceedings and no contingent liabilities requiring accrual or disclosure.
Most important facts for investors to verify
- Subsequent BeAT-HF post-market results, regulatory actions and any change to Barostim’s approved indication.
- Actual cash burn and liquidity runway against management’s three-year estimate, including progress and conditions for additional Innovatus loan tranches.
- Revenue growth, implant volumes, active centers and sales-force productivity, especially in the U.S.
- European MDR approval or transition extensions, and the effect of the CMS pass-through payment’s scheduled expiration on hospital economics.
- Whether gross-margin improvement can persist while commercial spending grows, and whether the company can reduce losses without materially slowing expansion.